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Aim: Qtracker®800 Vascular labels (Qtracker®800) are promising biomedical tools for high-
resolution vasculature imaging; their effects on mouse and human endothelia, however, 
are still unknown. Materials & methods: Qtracker®800 were injected in Balb/c mice, and 
brain endothelium uptake was investigated by transmission electron microscopy 3-h 
post injection. We then investigated, in vitro, the effects of Qtracker®800 exposure on 
mouse and human endothelial cells by calcium imaging. Results: Transmission electron 
microscopy images showed nanoparticle accumulation in mouse brain endothelia. 
A subset of mouse and human endothelial cells generated intracellular calcium transients 
in response to Qtracker®800. Conclusion: Qtracker®800 nanoparticles elicit endothelial 
functional responses, which prompts biomedical safety evaluations and may bias the 
interpretation of experimental studies involving vascular imaging.
Keywords:  calcium imaging • cytosolic calcium transients • human umbilical vein endothelial 
cells • mouse brain endothelium • nanoparticles • nanoparticle uptake • transmission electron 
microscopy
Cerebral vasculature imaging is required in 
the diagnosis of cerebrovascular pathology 
and healthcare stakeholders are increas-
ingly interested in safer, cheaper and higher 
resolution clinical imaging solutions. In 
the last decade, the field of nanotechnology 
has exploded, and new nanomedicine and 
nanoneuromedicine approaches have been 
proposed as alternative or complementary 
solutions to already existing vasculature 
imaging tools (e.g., MRI- and/or CT-based 
angiography).
Several metallic and organic nanoma-
terials have been approved by the US FDA 
at different clinical trial stages as diagnos-
tic tools; semiconductor nanomaterials (for 
example, quantum dots) are, on the other 
hand, generally considered for research use 
only [1,2]. Recently, a new generation of fluo-
rescent silica nanoparticles called Cornell 
dots (C-dots), with efficient urinary excre-
tion [3] and effective cancer-targeting proper-
ties [4,5], received FDA approval for clinical 
use. This FDA approval opens a new era for 
nanomedicine, and deeper understanding of 
cell-specific action of semiconductor-based 
nanoparticles is urgently needed.
Rapid nanotechnology advances in pre-
clinical brain vasculature imaging [6–10] have 
substantially increased our ability to unveil 
vascular contributions to the pathogenesis 
of brain ischemia, brain tumor formation, 
Alzheimer disease and epilepsy [11–13].
Quantum-dot nanoparticles (QDs) gained 
popularity over the last decade [14], due to their 
superior optical properties with respect to 
conventional organic dyes [15–17]. In particu-
lar, Qtracker® vascular labels (Qtracker®565, 
Qtracker®605, Qtracker®655, Qtracker®705 
and Qtracker®800, named according to their 
emission wavelength) have been designed for 
in vivo deep-tissue imaging of blood vessel 
distribution and morphological properties 
in small animals [18]. The high-wavelength 
Qtracker®800 allows the deepest imaging 
of tissue vasculature of the series. Preclinical 
in vivo imaging studies of the vessels using 
Qtracker®800 have already been carried out 
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to highlight mouse tumor vascularization [19] and bone 
marrow vasculature [20].
Biocompatibility is a key requirement for QD-based 
in vivo vascular imaging. The ‘ideal’ QDs should be 
‘inert’ with respect to the microenvironment (e.g., cir-
culating and endothelial cells). In practice, this desired 
property is usually sought by coating the QDs with a 
thin polymer layer, one of the most used being PEG, 
without any functional group. This layer reduces the 
nonspecific interaction of coated QDs with the sur-
rounding molecular species, including those present 
on the cell plasma membrane [18,21]. Indeed, PEG coat-
ing of QDs drastically minimizes nonspecific interac-
tions [18] and decreases cellular uptake rate, as proved 
in three tumor cell lines [22].
A very recent report, however, demonstrated the 
uptake of PEG-coated silica nanoparticles in brain 
endothelial cells [23]. Since these coated nanoparticles 
are between 25 and 100 nm (i.e., almost five- to ten-
times the core diameter of QDs) and given the authors’ 
claim that nanoparticle transport across the blood–
brain barrier is size-dependent, we wondered whether 
PEG-coated QDs might show significant interactions 
with endothelial cells. To our knowledge, there are no 
published reports describing such direct interaction.
Based on these premises, we investigated: whether 
in vivo Qtracker®800 are uptaken by endothelial cells, 
and the functional consequences of endothelial expo-
sure to Qtracker®800, studied in vitro. First, the hydro-
dynamic diameter of Qtracker®800 was estimated by 
dynamic light scattering (DLS) and the core size was 
calculated from electron microscopy images in order to 
characterize the nanoparticles. Next, in a set of in vivo 
experiments, Qtracker®800 uptake in mouse brain 
endothelia was investigated by electron microscopy. As 
previously described, many aspects of vascular endo-
thelium physiology are regulated by calcium signaling 
pathways, since most of the stimuli relaxing or con-
tracting brain capillaries act directly on the endothelial 
cells, producing changes in intracellular-free calcium 
concentration [24–26]. Based on the above, we also 
investigated in vitro the ability of a Qtracker®800 flux 
to induce fluctuations of free cytosolic calcium con-
centration and/or changes in mouse brain endothelial 
cell viability. We have also extended our in vitro study 
to another type of endothelial cells (human umbilical 
vein endothelial cells [HUVECs]) in order to discrimi-
nate between a specific effect on mouse brain endothe-
lial cells and an ubiquitous effect.
Materials & methods
Chemicals
Qtracker®800 (Q21071MP, lot #1216103, Life tech-
nologies, NY, USA) were dissolved in 0.9% saline solu-
tion for the in vivo studies, and in Ringer HEPES-buff-
ered solution (NaCl: 140 mM; KCl: 5.6 mM; MgCl
2
: 
2 mM; CaCl
2
: 2 mM; glucose: 10 mM; HEPES 
10 mM; pH 7.4 with NaOH) or phosphate-buffered 
solution (5 mM; pH 7.4) for the in vitro experiments. 
Fura-2 acetoxymethyl ester (Fura-2 AM) and pluronic 
acid F-127 (Life technologies) were dissolved in Ringer 
solution. All other reagents were purchased from 
Sigma-Aldrich (MO, USA).
Hydrodynamic size measurements by DLS
DLS was performed on Qtracker®800 using a Zeta-
sizer Nano ZS instrument (Malvern Instruments Ltd, 
MA, USA) operating with a 633 nm He-Ne laser light 
source and a fixed detector angle of 173°, as previously 
described [27]. Qtracker®800, 2-μM stock solution of 
2 μM in 50 mM borate buffer, pH 8.3 (Life Technol-
ogies) was diluted to the range of 40–80 nM either 
in Ringer solution or in saline solution (See section 
Chemicals). Lower particle concentrations resulted 
in poor signal/noise and large fit errors (using either 
single or multiple exponential models). Hydrodynamic 
diameter values were determined by averaging the 
intensity-weighted size distributions obtained from 20 
successive DLS runs of 10 s each. Measurements were 
repeated three-times and results are reported as mean 
± standard deviation (SD). The distribution widths 
were quantified by the Polydispersity Index (PdI). 
DLS measurements were carried out at 25°C before 
and after filtration (through acetate-cellulose Costar 
Spin-X Centrifuge Tube Filters, 0.22 μm pore size, 
Cole Parmer, USA) or centrifugation (18,000 × g for 15 
min) of Qtracker®800 solutions. No filtration or cen-
trifugation were used on the Qtracker®800 solutions 
employed for the in vivo and in vitro experiments.
Zeta potential measurements
Measurements were performed with a Zetasizer Nano ZS 
instrument (Malvern Instruments Ltd.). Qtracker®800 
particles were dispersed at a final concentration of 
75 nM in phosphate buffer, pH 7.4 and transferred to 
a disposable zeta cell. Measurements were carried out at 
25°C after 120 s equilibration time, performing seven 
runs comprising 12 subruns each. The applied voltage 
was 100 V and the measured conductibility was 4.540 ± 
0.334 mS cm-1. All measurements passed technical qual-
ity criteria based on inspection of phase and frequency 
plots, and were reproducible after sample spinning at 
18,000 × g for 15 min. Zeta potential was evaluated from 
electrophoretic mobility applying the Henry equation.
Animals & QD injection
Male Balb/c mice acquired from Harlan-Nossan 
(Udine, Italy) were adapted to the laboratory and 
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maintained on a 12-h inverted light/dark cycle, at 
23 ± 1°C, with access to food and water ad libitum. 
Experiments started when animals were 6 weeks old 
and weighed 25 ± 5 g.
Experiments were approved by the University of 
Verona ethical committee. Animals (n = 10) were 
divided into two equal groups, one received injection 
of saline solution and the other of Qtracker®800, and 
both groups were sacrificed 3 h after injection.
Qtracker®800 solutions (or saline) were adminis-
tered through a single injection (0.4 μM, 10 μl/g for 
each mouse) into the tail vein. Mice were then deeply 
anesthetized (zolazepam and tiletamine, ip. 20 mg/
kg), and perfused transcardially with PBS followed by 
phosphate-buffered 4% paraformaldehyde. Cortical 
brain samples were collected to evaluate Qtracker®800 
presence in the endothelium, based on transmission 
electron microscopy (TEM) and immunohistochem-
istry analysis.
According to the recommendation of the producer, 
the optimal time-interval for in vivo vasculature imag-
ing with Qtracker®800 is 3 h post-injection [18]. There-
fore, the 3-h time point is essential in understanding 
Qtracker®800 distribution into the cerebral blood-
stream and if this time interval is sufficient for the 
nanoparticles to interact with the mouse brain vascular 
endothelium.
Transmission electron microscopy 
Brain tissue samples were fixed in 2% glutaraldehyde 
in Sorensen buffer pH 7.4 for 2 h, postfixed in 1% 
osmium tetroxide in aqueous solution (2 h), dehy-
drated in graded concentrations of acetone and embed-
ded in Epon-Araldite mixture (Electron microscopy 
Sciences, PA, USA). Ultrathin tissue sections (70 nm) 
were placed on Cu/Rh grids with Ultracut E (Reichert, 
Wien, Austria) and were observed using a Morgagni 
268D microscope (Philips, The Netherlands).
For imaging the Qtracker®800 in solution, a drop-
let of nanoparticle solution was put on the grid (FCF-
150-Cu, Electron Microscopy Science, PA, USA) and, 
after drying, the grid was imaged without any other 
processing.
Human umbilical vein endothelial cell cultures
HUVECs from seven healthy donors were individu-
ally harvested as previously described [28] and used 
between passages 2 and 5. The medium was refreshed 
every 2 days. At the beginning of each experiment, 
cells were harvested by trypsinization, using 0.05% 
trypsin (Sigma-Aldrich) and 0.537 mM EDTA in 
phosphate-buffered saline without calcium and mag-
nesium (Seromed, Berlin, Germany). Cells were 
plated at a density of 2 × 104 cells/cm2 onto 24-mm 
cover glasses for intracellular calcium imaging 
measurements.
Mouse brain endothelial cell cultures
Primary cultures of brain microvascular endothe-
lial cells (BMVECs from Balb/c mice, passage 3–6; 
#PB-BALB-5023, PELOBiotech, Germany) were cul-
tivated according to the producer’s protocol. bEnd.3 
(passage 22–30; #ATCC® CRL-2299™, VA, USA), 
a Balb/c mouse cell line, was grown in DMEM with 
Glutamax-I, 10% fetal bovine serum (Gibco, NY, 
USA), 100 U/ml penicillin, 100 μg/ml streptomy-
cin, 5% CO
2
 (37°C). Cells were plated at a density of 
2 × 104 cells/cm2 onto 24-mm cover glasses for intra-
cellular calcium imaging measurements or 96-well 
plates for viability assays.
In-vitro Qtracker®800 studies
In order to apply Qtracker®800 in vitro in concentra-
tions comparable to those used for the in vivo studies, 
we first estimated that the above-described injections 
yielded blood concentrations around 44-nM nanopar-
ticles, based on a mouse whole blood volume of approx-
imately 2 ml [29]. Taking into account this approxi-
mate value and the range of concentrations previously 
reported for in vitro studies using Qtracker®655 [30], 
we used between 10 and 40 nM Qtracker®800 in our 
in vitro experiments. To shed light on the Qtracker®800 
direct action against brain microvascular endothelial 
cells, we performed calcium imaging and cell viability 
measurements on bEnd.3 cells and BMVECs.
Intracellular calcium imaging on endothelial 
cells
Fura-2 AM-based, Ca2+ imaging experiments on endo-
thelial cells were performed as previously described [31]. 
Images were captured using a cooled CCD camera 
(Clara, Andor, Northern Ireland) in a setup includ-
ing a monochromator Polychrome V (Till Photonics, 
Germany) coupled to an inverted microscope (Diaphot 
200, Nikon, Japan), and were acquired on a computer 
using an image acquisition software (Live Acquisition, 
Till Photonics, Germany). Solutions were delivered on 
top of the endothelial cells through a 100-μm quartz 
perfusion head using an 8-channel valve pressurized 
perfusion system (ALA Scientific Instruments, NY, 
USA). Cells were incubated with Fura-2 AM (2.5 μM) 
and pluronic acid (F-127, 0.01%) for 45 min. After 
15 min, the necessary time for Fura-2AM de-ester-
ification, the cells were imaged. Before starting the 
nanoparticle flux, the cell monolayer was perfused 
with Ringer HEPES-buffered for 5 min. Cytosolic 
Ca2+ transients were elicited by the administration 
of 20 nM Qtracker®800 for 5 min followed, after a 
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Ringer HEPES-buffered wash-out period of 10 min, 
by the application of either ATP (30 μM, 20 s) for 
BMVECs and bEnd.3 cells, or histamine (10 μM, 20 s) 
for HUVECs. ATP and histamine are topical vasoac-
tive substances that regulate brain capillary blood flow 
and vascular permeability [24,32], and were therefore 
used as positive controls for evoking intracellular cal-
cium transients in endothelial cells. Cells that did not 
show a response to the positive control were excluded 
from subsequent analyses.
Endothelial cell viability by Trypan blue assay
Trypan blue assay was performed on bEnd.3 and 
BMVECs in control conditions and after 24-h treat-
ment with Qtracker®800 (10, 20 and 40 nM). Cells 
were detached by trypsin, trypan blue was added 
(0.2%) and viable cells were counted (at least 150 cells). 
The viability was calculated relative to controls. Mea-
surements were done in three replicates. Cells exposed 
to 3 mM H
2
O
2
 (1 h) were used as positive control.
Data analysis
Data analysis was performed using OriginPro 8 
(OriginLab Corporation, MA, USA), Offline Acquisi-
tion software (Till Photonics, Germany) and Matlab 
(Mathworks, MA, USA).
Intracellular calcium changes were estimated from 
the ratio R = I
340 nm
/I
380 nm
 (I
340
 and I
380
 are the intensi-
ties measured at the emission wavelength of 510 nm 
when Fura-2 was excited at 340 and 380 nm, respec-
tively). The ratio R was calculated in regions of interest 
(ROIs) covering each cell in the microscope field, after 
background subtraction.
R values were corrected by subtracting baseline 
signals averaged over the 5 min of perfusion prior 
to the application of nanoparticles. The resulting 
ΔR values were used for subsequent analyses. Only 
responses with an amplitude higher than three-times 
the SD of the background noise (measured before QDs 
administration) were considered.
In view of the lack of standard quantitative meth-
ods to describe calcium transients in the literature [26], 
we defined a set of parameters characterising the sig-
nal envelope (Figure 1). The onset and offset of the 
response were marked by the signal raising above and 
descending below a 5% threshold of the peak ampli-
tude (ΔR
max
). Response latency was the time from 
beginning of nanoparticle perfusion to response onset. 
Total response duration was the interval between 
response onset and offset. In order to differentiate 
between fast transients with sustained late responses 
and signals reaching a peak later in time, we computed 
a response asymmetry ratio (b/a), where a is the time 
from response onset to peak, and b is the time from 
response peak to offset. Total response area was the 
integral over response duration. Finally, we computed 
the maximum slope of the ascending transient (V
max
). 
Pairwise correlations (along with Pearson and Spear-
man coefficients) among these parameters were com-
puted with custom Matlab scripts. One-way ANOVAs 
followed by Fisher LSD post hoc tests were used to 
assess BMVEC and bEnd.3 endothelial cell viability, 
comparing cells treated with different concentrations 
of Qtracker®800 to untreated controls.
Results
Characterization of nanoparticles (size, 
hydrodynamic diameter & zeta-potential)
We measured the hydrodynamic diameter of 
Qtracker®800 by means of the DLS technique. DLS 
measurements were performed on QDs dissolved in 
saline solution or in Ringer HEPES-buffered solution.
For both saline and HEPES-buffered Ringer 
solutions, we found in the intensity distribution 
plots a major peak centered near the expected size 
of Qtracker®800 (Figure 2A & B), as well as a minor 
peak corresponding to larger components (for exam-
ple, aggregates of nanoparticles). The DLS graphs in 
Figure 2 refer to 50 nM Qtracker®800, but note that 
the distribution did not significantly change for the 
analyzed range of nanoparticle concentrations (40–80 
nM). A global polydispersity index (PdI) of approxi-
mately 0.35 was determined for both solutions. The 
major, lower diameter peak can be attributed to iso-
lated Qtracker®800 particles. Given the wider scatter-
ing of larger particles, the relative populations of the 
species corresponding to the two peaks can be better 
appreciated after conversion of the data into a number 
distribution (dotted lines), which results in a single 
peak and confirms the prevalence of well-dispersed 
Qtracker®800 particles.
An attempt to remove the larger size contaminant by 
filtration was unsuccessful. On the other hand, centrif-
ugation followed by DLS measurements on the super-
natant resulted in very clean samples displaying a single 
peak in size distribution plots (Figure 2C &D). The mono-
modal distribution observed for these two preparations 
allowed us to perform a rigorous cumulant analysis and 
evaluate the harmonic intensity-averaged particle diam-
eter (Z-average). The Z-average of Qtracker®800 was 
36.56 ± 0.13 nm in Ringer HEPES-buffer (PdI = 0.180) 
and 35.80 ± 0.34 nm in saline solution (PdI = 0.151). 
The zeta potential value was -0.0124 ± 0.206 mV, indi-
cating that Qtracker®800 particles are essentially neu-
tral at pH 7.4. Qtracker®800 were also characterized by 
TEM (Figure 3A) and their cores, as visualized in sus-
pension, were irregular in shape and their longest axis 
measured on average 8.27 ± 1.27 nm (SD).
www.futuremedicine.com 3333
Figure 1. Relevant parameters in a calcium transient 
trace.
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Qtracker®800 accumulation in mouse brain 
microvascular endothelium
We then proceeded to evaluate the interaction of 
Qtracker®800 with the brain vascular endothelium in 
Balb/c mice upon nanoparticle injection. TEM analysis 
of mouse cortical brain sections indicated the presence 
of Qtracker®800 in the brain vascular endothelium 
3 h after the intravenous injection, the time window 
recommended by the nanoparticle producer for vascu-
lature imaging studies (Figure 3B & C). Nanoparticles 
can be detected in the cytoplasm, both concentrated 
within vesicle-like structures, and free in the cytosol. 
An in-depth histological characterization (sampling 
different brain regions and cellular compartments, dif-
ferent time-points or even different organs) of the of 
Qtracker®800 nanoparticle distribution is beyond the 
scope of the present study.
Qtracker®800 treatment does not lead to major 
cell death in vitro
Given the in vivo accumulation of Qtracker®800 in 
mouse brain endothelium demonstrated by TEM data, 
we have further verified, by in vitro tests, if nanopar-
ticle administration modified endothelial cell viability. 
Viability slightly decreased as a function of nanopar-
ticle concentration (BMVECs: F(3,8) = 5.25, p < 0.05; 
bEnd.3s: F(3,8) = 5.37, p < 0.05). Fisher post hoc tests 
confirmed that the reduction was statistically signifi-
cant only for the highest nanoparticle concentration, 
when viability dropped to about 93% (Figure 4).
Qtracker®800 generate intracellular calcium 
transients in mouse brain endothelial cells 
& human umbilical vein endothelial cells
As in vitro endothelial cell viability tests revealed only 
small effects on cell survival of Qtracker®800 in the 
concentration ranges relevant for in vivo imaging 
studies (see section Materials & methods, ‘In vitro 
Qtracker®800 studies’), we explored the possibility of 
more subtle, functional nanoparticle-induced altera-
tions of endothelial cells, by studying intracellular 
calcium fluctuations.
Acute (5 min) exposure to 20 nM Qtracker®800 
generated cytosolic calcium transients in BMVECs 
(Figure 5A), bEnd.3 cells (Figure 5B) and HUVECs 
(Figure 5C & D). Based on the inclusion criteria 
described above, we found that 13.7% (52/380 cells) 
of BMVECs and 13.9% (57/410 cells) of bEnd.3 
cells were responsive to Qtracker®800. Out of a total 
1796 studied HUVECs, 189 (or 10.5%) responded to 
Qtracker®800. Interestingly, the fraction of respon-
sive cells varied significantly between the seven donors 
(Figure 5D), suggesting the possibility that subjects may 
be either sensitive (20% or more of responsive cells) or 
nonsensitive (5% or less) to nanoparticles.
ΔR
max
 values induced by Qtracker®800 perfusion 
were on average a sizeable fraction of those induced in 
the positive control conditions. Namely, average ΔR
max
 
values for BMVEC and bEnd.3 cells were about ⅓ and 
½, respectively, of those produced by ATP administra-
tion; HUVEC cells had an average ΔR
max
 of about ⅔ of 
that induced by histamine administration (Figure 5E).
The quantitative analysis of calcium imaging record-
ings revealed a diversity of calcium transient profiles 
generated during the acute exposure of endothelial 
cells to the nanoparticle flux. The majority of observed 
calcium transients had a sharp onset, followed by a 
longer sustained response and decay (high asymmetry 
ratios). This pattern was substantially more marked in 
HUVECs than in mouse cells (Figures 5A–C & 6A).
In spite of certain commonalities, responses dif-
fered in several respects among cell types (Figure 6A). 
HUVEC transients showed the highest mean ampli-
tude, area and duration (Figure 6A), in other words, 
they produced the strongest responses to nanopar-
ticle administration. HUVEC transients were also 
highly asymmetrical (∼three-times more than the 
mouse endothelial transients). Interestingly, the 
ΔR
max
 and V
max
 distributions were remarkably simi-
lar. Indeed, a strong and highly significant correlation 
between the two parameters was observed (Figure 6B, 
upper panels. See also Supplementary Figures 1–3, 
Supplementary Material, for a complete presenta-
tion of the correlations and distribution histograms). 
This suggests that a very rapid increase in the ascend-
ing phase of the transient tends to produce high peak 
amplitudes. Even more important is the fact that the 
slope of the linear regression was very similar between 
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Figure 2. Distribution of Qtracker®800 particle sizes measured by dynamic light scattering. (A) Qtracker®800 in Ringer HEPES-buffer 
solution; (B) Qtracker®800 in saline solution; (C) same as (A) after centrifugation; (D) same as (B) after centrifugation. Histograms 
are size distribution by intensity plots (left y-axes). Error bars show the SD of three replicate measurements. Dotted curves in (A & B) 
correspond to number distribution plots (right y-axes) obtained by conversion from the underlying intensity distributions.
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cell types. This suggests a common mechanism of cal-
cium transient triggering, irrespective of endothelial 
types.
On the other hand, response latencies were similar 
across endothelial cell types, again suggesting a com-
mon triggering mechanism. Additionally, an inter-
esting pattern was observed when plotting response 
latencies against V
max
 (Figure 6B, lower panels). The 
charts suggest that cells with relatively short latencies 
are characterized by a wide range of response transient 
velocities, while longer latencies were associated with 
relatively slower transients. In other words, delayed 
transients tended to be restricted to less steep ascend-
ing transients (smaller V
max
) and consequently smaller 
amplitude.
Discussion
In this study, we report for the first time a functional 
interaction of Qtracker®800 with the brain vascu-
lar endothelium. In particular, we found that: QDs 
may be uptaken in vivo by brain endothelial cells; the 
interaction between QDs and endothelial cells results 
in the activation of free cytosolic calcium signaling in 
primary and immortalized brain endothelial cells, as 
well as in human umbilical vein endothelial cells; such 
activation does not appear to be related to cytotoxicity, 
resulting instead in interferences with normal calcium-
mediated signal transduction pathways; HUVEC data 
indicate a high interindividual variability of QDs-cell 
interaction susceptibility.
Nontargeted PEGylated near-infrared emitting 
Qtracker®800 accumulate in brain vascular 
endothelium
Previous studies demonstrated the uptake by endothe-
lial cells of different functionalized and/or targeted 
PEGylated quantum dots [33–35], but not of nontar-
geted Qtracker® Vascular labels. The latter nanopar-
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Figure 3. Transmission electron microscopy images on Qtracker®800 and their accumulation in Balb/c mouse 
brain endothelium. (A) Qtracker®800 in suspension; scale bar: 100 nm. (B) Qtracker®800 in vivo accumulation in 
brain vascular endothelium, 3 h after intravenous injection; scale bar: 1 μm. (C) Detailed image of nanoparticle 
accumulation in the endothelium; scale bar: 100 nm.
Figure 4. Viability of brain microvascular endothelial 
cells upon 24 h in vitro exposure to Qtracker®800. 
Percentage of viable cells (means ± standard deviation) 
obtained by Trypan blue assay on brain microvascular 
endothelial cells and bEnd.3 cells exposed for 24 h 
to 0, 10, 20 and 40 nM Qtracker®800 and 3 mM H2O2 
(positive control). Statistically significant differences 
(p < 0.05) from the control (0 nM) conditions are 
indicated by an asterisk (*). 
bEnd.3: Brain endothelial cell line derived from 
mice cerebral cortex; BMVEC: Brain microvascular 
endothelial cells from Balb/c mice in primary culture; 
QD: Quantum dot.
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ticles can be uptaken in different cell types [30,36–38], 
but to our knowledge no reports are available for endo-
thelial cells. Furthermore, uptake of Qtracker®800 has 
not been reported for any cell type.
Endocytosis, which is thought to be the main path-
way for nanoparticle internalization [39,40], depends on 
nanoparticle size [41]. Specifically, endocytosis-medi-
ated uptake of nanoparticles was found to be more 
efficient for hydrodynamic diameter values around 
50 nm [42]. In this respect, although the optical quali-
ties of Qtracker®800 make it suitable for deep vascu-
lature imaging, their high hydrodynamic diameter 
(∼35–36 nm based on our data) compared with the 
other dyes of the Qtracker® vascular label series (the 
second largest being the 26.6 nm Qtracker 705 [43]), 
makes them potentially more prone to endocytic inter-
nalization.
In in vivo or cell-culture experiments, the issue of 
nanoparticle fate is further complicated by the very 
complex media (blood, cell-culture medium) with 
which they interact. Very recent reports show the 
strong dependence of nanoparticle aggregation, par-
ticularly quantum dots, with respect to medium com-
position and coating structure [44,45]. Even in a simpler 
solution, bovine serum albumin in PBS, the hydro-
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Figure 5. Qtracker®800 evoked (Ca2+)i transients in mouse and human endothelial cells (see facing page). 
Representative traces of ΔR over time for (A) brain microvascular endothelial cells; (B) bEnd3, and (C) HUVECs. 
An endogenous control response was evoked by ATP (30 μM) in (A & B), and by histamine (10 μM) in (C). 
(D) HUVECs’ sensitivity to Qtracker®800 exposure, where responsive cells are considered those able to generate 
intracellular calcium transients upon brief exposure (5 min) to Qtracker®800. Percentage of responsive (gray) and 
nonresponsive (white) endothelial cells from different donors. The number of Qtracker®800-responsive cells are 
plotted against the total number of tested cells in separate columns for each donor (D1–D7). The percentages 
of responsive cells for each donor are: D1: 1.25%; D2: 27.87%; D3: 19.69%; D4: 1.35%; D5: 26.76%; D6: 5.45%; 
D7: 2.29%. (E) ΔRmax for BMVEC, bEnd.3 and HUVEC in response to Qtracker
®800 and to ATP or His, respectively. 
bEnd.3: Brain endothelial cell line derived from mice cerebral cortex; BMVEC: Brain microvascular endothelial 
cells from Balb/c mice in primary culture; D: Donor; His: Histamine; HUVEC: Human umbilical vein endothelial cell; 
QD: Quantum dot.
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dynamic diameter of Qtracker®800, as measured by 
DLS, increased with albumin concentrations, becom-
ing more than double at protein concentrations equiv-
alent to those present in the mouse blood serum [46]. 
Blood fibrinogen was also proven to strongly bind 
Qtracker®800 [47]. In this context, it is very difficult 
to further speculate about the mechanism by which 
Qtracker®800 particles are uptaken into the cells.
A vascular label such as the Qtracker® nanoparticles 
is expected to be inert with respect to the physiology 
of the target system. Our study, however, shows that 
nontargeted, near-infrared emitting Qtracker®800 are 
captured by the brain vascular endothelium in the first 
3 h upon vein injection, which raises important con-
cerns, including the possibility that such uptake (and 
interaction more in general) may lead to alteration of 
endothelial cell functionality.
Qtracker®800 alters ‘normal’ calcium signaling 
in brain endothelial cells
It was previously shown that acute exposure (5–30 
min) to non-PEGylated or functionalized QDs elicits 
in vitro cytosolic calcium increases in different excit-
able and nonexcitable cells [48–51]. Our study points 
out that nanoparticle PEG-ylation, at least in the case 
of Qtracker®800, does not prevent functional conse-
quences on the vascular endothelium, as revealed by 
the occurrence of calcium transients during the 5-min 
exposure.
The vascular endothelium has mechanosensitive 
properties, as part of the adaptation to the perma-
nent shear stress exerted by the bloodstream. Endo-
thelial cells may react to mechanical stimuli through 
a variety of mechanisms, such as transient receptor 
potential channels, ATP-operated cation channels, 
GTP-binding protein coupled receptors and adhesion 
molecules [52]. In turn, a variety of downstream intra-
cellular signaling pathways are activated, the majority 
involving either calcium release from internal stores, 
the intake of extracellular calcium or both [51,53]. The 
strong positive correlation between calcium release 
amplitude (ΔR
max
) and steepness (V
max
) shown in 
the present study has similarities with the previously 
reported amplitude-dependent calcium release in 
response to local mechanical stimuli [54] and might 
imply that Qtracker®800 act as a mechanical trigger 
for the calcium-induced transients.
The wide range of calcium event latencies we have 
observed, and the fact that only a subset of cells were 
activated, lead to the following speculation. Some cells 
are triggered by a probabilistic, direct interaction with 
the nanoparticles (possibly of mechanical nature) while 
neighboring cells are indirectly recruited in a wave of 
calcium events through intercellular communication 
mechanisms, as previously described in other endo-
thelial cell types [55]. In this view, while fast and steep 
transients could be the result of direct nanoparticle-to-
cell interactions, slower and shallower transients could 
be related to indirect activations.
Qtracker®800 might activate different 
components of the neurovascular unit
It has already been stated that brain microvascular 
endothelium is a major component of the neurovas-
cular unit, playing essential roles in physiological and 
pathological neuronal-activation states [11,56,57]. The 
spatio-temporal Ca2+ dynamics contribute to many 
physiological properties of the vascular intima [26]; 
asynchronous and synchronous Ca2+ waves control 
vascular tone [58]. Local changes at the level of vas-
cular endothelium (e.g., leukocyte-endothelial adhe-
sion, leukocyte rolling) can translate into alterations 
of neuronal excitability [11]. In this general context, 
the Qtracker®800-induced intracellular endothelial 
Ca2+ transient activation shown by our results deserves 
attention in nanomedicine, and might imply not only 
localised endothelial Ca2+ events but also the initia-
tion of a complex signaling pathway involving mul-
tiple components of the neurovascular unit. Previous 
studies have highlighted the action of nanoparticles 
on different components of the neurovascular unit, 
by demonstrating that Qtracker®705: accumulate 
in vitro in primary cortical cultures; activates astro-
cytes after microinjection in brain cortex [36]. Fur-
thermore, large silica (NH
2
) PEGylated nanoparticles 
in vitro are uptaken into bEnd.3 cells and, in vivo, are 
transported across the blood-brain barrier in Balb/c 
mice [23].
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Figure 6. Analysis of the parameters in Qtracker®800-induced calcium transients (see facing page). (A) Distributions of each of the six 
calcium transient parameters (y-axis label) defined in the ‘Materials & methods’ section. The boxplots show the median, 25% and 75% 
percentiles. In addition, the mean (□), 1% and 99% percentiles (×), and the minimum and maximum data points ( _) are reported. 
(B) Correlations between selected parameter pairs for each cell type (the linear fit with Pearson coefficient – P, and the confidence 
level – p – are presented for the upper panels). See Supplementary Material for the complete pairwise correlation matrices. 
BMVEC: Brain microvascular endothelial cells from Balb/c mice in primary culture; HUVEC: Human umbilical vein endothelial cell; 
Vmax: Maximum slope of the ascending calcium transient. 
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Based on our data, we wonder whether 
Qtracker®800-induced alteration of ‘normal’ calcium 
signaling in endothelial cells may bias the interpreta-
tion of results in studies of brain vascular function 
where nanoparticles are used as labels.
How suitable are Qtracker®800 for 
translational studies?
Our results indicate that the nanoparticle-induced 
endothelial activation is not specific to mouse brain 
vessels, but it extends at least to a different species 
(human) and a different endothelial cell localization 
(umbilical vein). A further generalization of the obser-
vation will require ad hoc studies on endothelial cells 
derived from other species and organs.
A key result in our study is the striking difference 
in HUVEC sensitivity to Qtracker®800 from one 
donor to another (almost an all-or-none effect). Our 
data agree with previously reported donor-dependent 
variability of HUVECs exposed to laminar shear 
stress [59], and might have implications for the use 
of near-infrared-emitting quantum dots in clinical 
vascular imaging applications.
Whether a similar donor-dependent variability of 
responses in HUVECs exists also in rodents is not 
easy to establish, since in vitro studies make use of 
sample pooling between several subjects (approxi-
mately ten mice for a single culture [60]). But this is a 
relevant issue, because if on one hand the mean num-
ber of activated cells in mice and in humans are com-
parable (13.7 vs 10.5%) establishing potential effects 
based on such averages might underestimate the 
effects on the individuals more prone to QD-induced 
activations.
Conclusion & future perspective
Our study partly fills the knowledge gap regarding the 
interaction of near-infrared-emitting Qtracker®800 
nanoparticles with biological systems, in particular the 
brain vascular endothelium. Both in vitro and in vivo 
data indicate the accumulation of QDs in the vascular 
endothelium as well as functional effects revealed by 
intracellular calcium changes in a subset of cells. In 
addition, we observed substantial interindividual dif-
ferences in HUVEC activation. Altogether, the find-
ings raise two types of concern: in studies of vascular 
function in living animals, the use of QD-based label-
ing might bias the results in difficult-to-detect ways; in 
view of possible clinical applications, the between-sub-
ject variability in susceptibility may complicate safety 
assessments.
Undoubtedly, brain vasculature imaging tech-
niques can greatly benefit from the use of nanoparti-
cle labels. On the other hand, as we have shown, such 
labels may be internalized by and functionally inter-
act with blood vessel endothelia, which raises obvi-
ous safety concerns. It is quite possible that the effects 
uncovered represent the tip of an iceberg, and that 
further studies are necessary to better characterize 
the full extent and consequences of the activations. 
Ideally, the development of novel labels should be 
focused on reducing or eliminating their interactions 
with biological tissues. Considering the vast potential 
of these nanoparticles for brain vasculature imaging, 
we hope that further chemical engineering will opti-
mize their biostability, biocompatibility and efficient 
clearance profile.
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Executive summary
Aim
•	 To assess the possible interaction of Qtracker® 800 Vascular labels (Qtracker®800), a powerful nanotechnology 
tool for biomedical vasculature imaging, with mouse and human endothelium.
Results
•	 Transmission electron microscopy showed Qtracker®800 accumulation in mouse brain microvascular 
endothelium 3 h after their administration.
•	 Mouse brain endothelial cells, both in primary and immortalized cultures, are Qtracker®800-sensitive; 14% of 
cells generate intracellular calcium transients during acute 5-min exposures.
•	 Human umbilical vein endothelial cells in primary culture derived from different donors present substantial 
variability in transient calcium responses (0 ÷ 30%) when acutely exposed to Qtracker®800.
•	 The chronic in vitro exposure to Qtracker®800 for 24 h did not reveal major changes in endothelial cell 
viability.
Conclusion & future perspective
•	 We demonstrated a direct action of Qtracker®800 on the vascular endothelium in the first 3 h after 
administration, thus overlapping the time window recommended for vasculature imaging studies with these 
fluorescent nanoparticles.
•	 Keeping in mind the enormous potential of Qtracker®800 deep-tissue penetration in biomedical applications, 
better manufacturing solutions to diminish/eliminate endothelium actions should be found.
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